By Professor David Simon Ziegler

Journal articles

McKay CJL; Mayoh C; Power P; Jessop S; Sriharan S; Staunton J; Trinder S; Zhukova N; Mignone C; Govender D; Alvaro F; Downie P; Hansford JR; Hassall T; Valvi S; Mateos MK; Barahona P; Gifford AJ; Tax G; Tsoli M; Dolman EM; Wong M; Cowley M; Marshall GM; Trahair TN; Ekert PG; Haber M; Tyrell V; Lau LMS; Manoharan N; Ziegler DS; Khuong-Quang DA, 2026, 'Precision-guided therapy in H3K27-altered diffuse midline glioma', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-73304-9

Ross SE; Holliday H; Wang E; Zeraati M; Tsoli M; Ziegler DS; Dinger ME, 2026, 'RNA N6-methyladenosine (m6A) regulates cell cycle progression in diffuse midline glioma (DMG) and confers sensitivity to FTO inhibition', Cell Death and Disease, 17, http://dx.doi.org/10.1038/s41419-026-08647-8

Hetherington K; Hunter JD; Donoghoe MW; McGillycuddy M; McGill BC; Robertson EG; Tyrrell V; Lau LMS; Marron JM; Tucker KM; Marshall GM; Vetsch J; Haber M; Malkin D; Mateos MK; O’Brien TA; Ziegler DS; Wakefield CE, 2026, 'Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer', npj Genomic Medicine, http://dx.doi.org/10.1038/s41525-026-00591-y

Fordham AM; Brown LM; Mayoh C; Salib A; Barger ZA; Wong M; Lim Kam Sian TCC; Hu C; Xie J; Gunther K; Trebilcock P; Terry RL; Barahona P; Ajuyah P; Sherstyuk A; Avila A; Cadiz R; Perkins CM; Gifford AJ; Mao J; Dolman MEM; Zhao A; O’Regan LP; Gorgels D; Lau LMS; Ziegler DS; Haber M; Tyrrell V; Lock RB; Cowley MJ; Nicholls W; Daly RJ; Ekert PG; Fleuren EDG, 2026, 'Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young', Molecular Cancer Therapeutics, 25, pp. 1077 - 1094, http://dx.doi.org/10.1158/1535-7163.mct-25-0736

Hetherington K; Hunter J; Donoghoe M; McGillycuddy M; McGill B; Robertson E; Tyrrell V; Lau L; Marron J; Tucker K; Marshall G; Vetsch J; Haber M; Malkin D; Mateos M; Brien TO; Ziegler D; Wakefield C, 2026, 'ID #107 Family experiences of precision-guided treatment recommendations for poor prognosis paediatric Central Nervous System (CNS) cancer', Neuro-Oncology Pediatrics, 2, pp. wuag026.020, http://dx.doi.org/10.1093/neuped/wuag026.020

Manoharan N; Gargett T; Khan S; Yeo E; Truong N; Gardam B; Vittorio O; Tsoli M; Shai-Hee T; Salomon R; Mayoh C; Li W; Ebert L; Pillai S; Jacobson E; Wong L; Mitchell L; Mateos M; Avard R; Trickett A; Nelson A; Mitchell R; Monje M; Brown M; Ziegler D, 2026, 'ID #1113 Low dose intravenous autologous third generation GD2-CAR-T cell therapy in diffuse midline glioma patients: anti-tumour activity with minimal toxicity', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.501

Hansford J; Valvi S; Dodgshun A; Manoharan N; Moore C; Hassall T; De Luca C; Dawes L; Goldstein R; Waddell N; Khanna R; Taranath A; McEniery J; Strong R; Kirby M; Hernandez E; Romanoff L; Hummel T; Ziegler D; Lau L; Krishnan R; Panicker G; Oliviera L; Liu J; Hudson A; Olsen K; Dube C; Orozco NM; Wainwright B, 2026, 'ID #112 PAEDNEOVAX - Multicentre, investigator-initiated phase I/II study to assess safety and efficacy of personalised mRNA vaccine targetting tumour-associated neoantigens in children and young adults with high-risk brain tumours.', Neuro-Oncology Pediatrics, 2, pp. wuag026.021, http://dx.doi.org/10.1093/neuped/wuag026.021

Lazow M; Schieffer K; Thomas D; Paulson V; Cole B; Fuller C; Valvi S; Gottardo N; Fisher M; Plant A; Salloum R; Crotty E; Hwang E; Das A; Tabori U; Gorsi H; Chi S; Leary S; Baxter P; Hawkins C; Hubank M; Jacques T; Jones D; Sahm F; Cowley M; Ziegler D; Rodriguez M; Dyke J; Robertson T; Palmer J; de Blank P; Anh D; Quang K; Troyer K; Konkle B; Tanaka R; Drissi R; Mardis E; Hargrave D; Jones C; Fouladi M, 2026, 'ID #1122 Preliminary feasibility of an international, multidisciplinary central screening platform for the CONNECT TarGeT molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG)', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.507

Super L; Wood P; Martin M; Dorval P; Kumar B; St john A; White C; Sylvester D; Fuentes-Bolanos N; Stengs L; Levine A; Hawkins C; Das A; Tabori U; Ziegler D; Lau L; Barahona P; Zhukova N; Quick J, 2026, 'ID #1128 Lynch syndrome-associated high-grade glioma in adolescence: implications of integrated molecular profiling for diagnosis and therapy', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.511

Nagabushan S; Sidpra J; Jacqus T; Sudhakar S; Biswas A; Lind V; Patel R; Piccirilli E; Colafati G; Mastronuzzzi A; Lall N; Bajaj M; Avsenik J; Kitanovski L; Ryan M; Wadhwani N; Gojo J; Gómez-Chiari M; Muchart Lopez J; Morales A; Madrid L; Solano P; Mushtaq N; Guimaraes C; Lequin M; Hayes L; Agarwal V; Markart S; Mordasini P; Dineen R; Hjort M; Govender D; Dholaria H; Moloney S; Hansford J; Hoffman L; Blank C; van Zanten S; Damen-Korbijn C; Nussbaumer G; Ronsley R; Hargrave D; Abdelbaki M; Chacko G; Balakrishnan R; John R; Jasper A; Mankad K; Ziegler D, 2026, 'ID #140 Clinical, Radiological and Molecular Characteristics of H3K27M-mutant Pediatric Primary Spinal Diffuse Midline Glioma: An International Multi-registry and Institutional Study', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.031

Cheung B; Gadde S; Ng SW; Chung N; Liu J; Tsoli M; Doughty L; Nero T; Parker M; Endersby R; Kumar N; Chesler L; Ziegler D; Marshall G, 2026, 'ID #311 Targeting MYC-driven vulnerabilities in lethal childhood brain tumours using a first-in-class brain-penetrant MYC degrader', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.091

Michniewicz F; Rouaen J; Cazzoli R; Shai-Hee T; Ehteda A; Faridi P; Vitanza N; Tsoli M; Ziegler D; Vittorio O, 2026, 'ID #421 Copper deprivation disrupts epigenetic, kinase, and metabolic signaling to induce DNA damage and mitotic failure in Diffuse Midline Glioma', Neuro-Oncology Pediatrics, 2, pp. wuag026.142, http://dx.doi.org/10.1093/neuped/wuag026.142

Lawrence D; Upton D; Tax G; Holliday H; Ung C; Gopalakrishnan A; Liu J; Emmy M; Dolman M; Roebuck J; Mao J; Sivanathan A; Cai D; Rayner B; Tsoli M; Ziegler DS, 2026, 'ID #429 Therapeutic development of the clinically active compound ACT001 with Mcl-1 inhibitors for the treatment of paediatric diffuse midline glioma', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.148

Lehmann R; Zhang E; Zhu J; Mayoh C; Lee A; Nguyen H; Tsoli M; Rayner B; Ziegler D, 2026, 'ID #500 Novel therapeutic targets in drug-resistant BRAFV600E paediatric high-grade glioma', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.183

Lee G; Chen Y; Gopalakrishnan A; Liu J; Lawrence D; Holliday H; Tsoli M; Kin Ip KC; Ziegler D, 2026, 'ID #598 Unravelling the Role of Neural Progenitor Cells in the Development of Paediatric High-Grade Glioma', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.228

McGill B; Hetherington K; McGillycuddy M; Daly R; Ziegler D; Mateos M; Marshall G; Wakefield C, 2026, 'ID #661 Psychological distress in parents of children with poor prognosis central nervous system (CNS) cancers participating in the PRISM precision medicine trial', Neuro-Oncology Pediatrics, 2, pp. wuag026.264, http://dx.doi.org/10.1093/neuped/wuag026.264

Young E; Govender D; Waldeck K; Gottardo N; Strong R; Kinross K; Carr M; Jones J; Wong L; Ziegler D; Hansford J; Michael M; Tremblay C; Rudkin A; Winstanley M; Desai J; Ashley D; Cain J; Wood P, 2026, 'ID #672 A phase II study of continuous low dose panobinostat in paediatric patients with atypical teratoid rhabdoid tumours (ATRT).', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.271

Soleymani S; Hetherington K; McGill B; Ziegler D; Mateos M; Wakefield C, 2026, 'ID #673 Bereaved Parents’ Reflections on PRISM Precision Medicine Trial Participation for Poor-Prognosis Paediatric CNS Cancer', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.272

Sanguino YC; Fox S; Cassim A; Rodriguez de la Fuente L; Li S; Jackson E; Duchatel R; Holliday H; Gopalakrishnan A; Tsoli M; Ziegler D; Ortega DG; Dun M; Mora FV, 2026, 'ID #674 Unmasking Epigenomic Vulnerabilities in Diffuse Midline Glioma to Guide Epigenetic Therapy', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.273

Tax G; Mao J; Fuller L; Lau LMS; Mayoh C; Cadiz R; Zhou A; Zaman M; Thomson N; Xie J; Ekert PG; Ziegler DS; Dolman EM, 2026, 'ID #676 Precision-Guided Oncology for Pediatric Brain Tumors Using Functional Ex Vivo Drug Sensitivity Profiling', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.275

Mateos M; Manoharan N; Anh D; Quang K; Chen W; Salomon R; Shale C; Ong F; Sriharan S; Valvi S; Nicholas S; Mayoh C; Toumari M; Li W; El-Kamand S; Wong M; Hansford J; Alvaro F; Bazaz SR; Cui L; Tyrrell V; Cuppen E; Haber M; Ekert P; Priestley P; Ziegler D; Lau L; Cowley M, 2026, 'ID #736 Ultra-sensitive plasma ctDNA assay enables detection of brain tumour DNA in peripheral blood and is prognostic in childhood brain cancer', Neuro-Oncology Pediatrics, 2, pp. wuag026.309, http://dx.doi.org/10.1093/neuped/wuag026.309

Lawrence D; Curnow JW; Ung C; Liu J; Chen Y; Roebuck J; Tax G; Emmy M; Dolman M; Rayner B; Ziegler DS; Tsoli M, 2026, 'ID #771 Inhibition of MCL-1-mediated anti-apoptotic signalling as a potential therapeutic strategy for paediatric high-grade gliomas', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.326

Acosta AM; Gonzales-Aloy E; Ahmed-Cox A; Kurniawan N; Sivaram A; Tsoli M; Janjua T; Kokil G; Ziegler D; Mccarroll J; Turecht K; Popat A; Kumeria T; Kavallaris M, 2026, 'ID #811 Modelling the human blood-brain barrier in 3D to accelerate nanoparticle delivery strategies for brain cancer', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.339

Khuong Quang DA; Landi D; Kline C; Hargrave D; Leary S; Van der Lugt J; Mueller S; Nysom K; Perreault S; Waanders A; Witt O; Ziegler D; Manley P; Zhang J; Barry E; Maher J; Kilburn L, 2026, 'ID #832 FIREFLY-1 3-Year Results: Impact of Prior Therapy on Tovorafenib Activity in BRAF-Altered Pediatric Low-Grade Glioma', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.351

Bell JL; Lim T; McKie W; Tax G; Abruzzese D; Roebuck J; Nguyen H; Tsoli M; Faridi P; Dolman E; Vittorio O; Vitanza N; Ziegler D, 2026, 'ID #867 Targeting lactate production pathways as a novel therapy against DIPG', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.368

Khan A; Gopalakrishnan A; Liu J; Mayoh C; Burns M; Rayner B; Tsoli M; Ziegler D, 2026, 'ID #95 Dual polyamine pathway blockade synergises with irinotecan to eradicate MYC-driven medulloblastoma', Neuro-Oncology Pediatrics, 2, http://dx.doi.org/10.1093/neuped/wuag026.017

Debily MA; Le Teuff G; Kergrohen T; Varlet P; Castel D; Leblond P; Hargrave D; Nysom K; Blomgren K; McCowage GB; Bautista F; van Vuurden D; Jones C; Mackay A; Izquierdo E; Ziegler DS; Moussa A; Barret E; Puget S; Beccaria K; Aquilina K; Riffaud L; Bolle S; Abbou S; Bertozzi AI; De Carli E; Boddaert N; Dangouloff-Ros V; Calmon R; Blanc P; Vassal G; Le Deley MC; Grill J, 2026, 'Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial', Nature Medicine, 32, pp. 2201 - 2215, http://dx.doi.org/10.1038/s41591-026-04354-1

Fuentes-Bolanos NA; Courtney EK; Mayoh C; Warby M; Lau LMS; Wong-Erasmus M; Khuong-Quang DA; Barahona P; Padhye B; Warren N; El-Kamand S; Nunag S; Ajuyah P; Sherstyuk A; Altekoester AK; Sullivan A; Poplawski N; Kiraly-Borri C; O’sullivan S; Fan HM; Alli R; Curnow L; Bhatia K; Anazodo A; Trahair TN; Mateos MK; Hansford JR; Dholaria H; Josephi-Taylor S; Moore AS; Nicholls W; Gottardo NG; Downie P; Khaw SL; Tapp H; McCowage G; Dalla-Pozza L; Alvaro F; Wood PJ; Tyrrell V; Haber M; Cowley MJ; Ekert PG; Marshall GM; Kirk J; Tucker K; Pinese M; Ziegler DS, 2026, 'Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer', Clinical Cancer Research, 32, pp. 2047 - 2059, http://dx.doi.org/10.1158/1078-0432.CCR-25-3806

Zhu J; Tsoli M; Bertoldo J; Mueller S; Ziegler DS, 2026, 'A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma', Neuro Oncology Advances, 8, pp. ii41 - ii58, http://dx.doi.org/10.1093/noajnl/vdaf008

Kline C; Landi D; Khuong-Quang D-A; Nysom K; Kilburn LB; Waanders AJ; Perreault S; Mueller S; McCowage G; Driever PH; Leary SES; Ziegler DS; Kang HJ; Witt O; Baxter PA; Bailey S; Chi SN; Han JW; Abdelbaki MS; Hassall TE; Franson AT; Hargrave D; Toledano H; Oren MY; Jabado N; Gottardo NG; Gerber NU; Renzi S; Segal D; Tan EEK; Oren L; Whipple NS; Hansford JR; Pehlivan K; Zhang J; Manley P; Ott L; Barry E; Maher JC; van der Lugt J, 2026, 'Clinical stability after tovorafenib treatment in patients with relapsed/refractory pediatric low-grade glioma: Updated results from the phase 2 FIREFLY-1 trial', Neuro-Oncology Pediatrics, 2, pp. wuag022, http://dx.doi.org/10.1093/neuped/wuag022

Lee YHG; Tsoli M; Shi YC; Ip CK; Ziegler D, 2026, 'Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development', Cancer and Metastasis Reviews, 45, http://dx.doi.org/10.1007/s10555-026-10325-2

Holliday H; Khan A; Ehteda A; Nguyen H; Ross SE; Jayatilleke N; Gopalakrishnan A; Wang E; Sanguino YC; Kavanagh D; Guo X; Liu J; Lawrence D; Sun CX; Lehmann R; Ip CK; Lee A; Rangel-Sanchez L; Li W; Salomon R; Firestein R; Weatheritt RJ; Valdes-Mora F; Dinger ME; Phoenix TN; Mayoh C; Rayner BS; Tsoli M; Ziegler DS, 2026, 'Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma', Science Translational Medicine, 18, http://dx.doi.org/10.1126/scitranslmed.adr1557

McKay S; Elias J; Mazariego C; Tyedmers E; Morrow A; Wakefield CE; Ziegler DS; Smith JD; Taylor N, 2026, 'A single logic model capturing clinical, service, and implementation interventions using a practical example in pediatric precision medicine', Jbi Evidence Implementation, http://dx.doi.org/10.1097/XEB.0000000000000600

Gereis JM; Hetherington K; Robertson EG; Daly R; McGill BC; Ziegler DS; Wakefield CE, 2025, 'Animated videos for childhood cancer precision medicine: development and evaluation with parents and patients', Supportive Care in Cancer, 33, http://dx.doi.org/10.1007/s00520-025-10191-8

Hanssen KM; Murray J; Pandher R; Alfred S; Gamble LD; Brand J; Mosmann E; Kusuma FK; Mak C; Kearns A; Kamili A; Atkinson C; Minchaca AZ; Bertoldo J; Ziegler DS; Mussai F; Cheng PNM; Norris MD; Fletcher JI; Haber M, 2025, 'Arginine depletion potentiates standard-of-care chemo-immunotherapy in preclinical models of high-risk neuroblastoma', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03502-8

Ignacio RMC; Forgham H; Ma Z; Jensen A; Sharbeen G; Ruan J; Ziegler DS; Tsoli M; Phillips PA; Mayoh C; Kavallaris M; McCarroll J, 2025, 'Chemotherapy reprograms miRNA expression profiles in apoptotic extracellular vesicles from medulloblastoma cells, regulating pro- and anti-proliferative effects on recipient drug-naïve cells', Cell Communication and Signaling, 23, http://dx.doi.org/10.1186/s12964-025-02241-9

Barlow-Stewart K; Courtney E; Cowley M; Ebzery C; Fuentes Bolanos N; Gifford AJ; Harden H; Josephi-Taylor S; Kotecha RS; Mateos MK; Manzur M; Mayoh C; Milnes D; Nielsen J; O’Connor M; Padhye B; Pitman C; Pitman E; Pinese M; Speechly C; Sullivan A; Trahair T; Tucker K; Tyrrell V; Warby M; Wood A; Ziegler DS; Johnston C, 2025, 'Returning raw genomic data to research participants in a pediatric cancer precision medicine trial', Npj Genomic Medicine, 10, http://dx.doi.org/10.1038/s41525-025-00470-y

Kline C; Hargrave D; Khong-Quang D-A; Landi D; Leary S; van der Lugt J; Mueller S; Nysom K; Perreault S; Waanders A; Witt O; Ziegler D; Manley P; Zhang J; Barry E; Kilburn L, 2025, 'CTP-17. Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial', Neuro-Oncology, 27, pp. v149 - v149, http://dx.doi.org/10.1093/neuonc/noaf201.0589

Duchatel RJ; Savary C; Germon ZP; Riley M; Ziegler DS; Mueller S; Jackson ER; Dun MD, 2025, 'Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas', Neuro Oncology, 27, pp. 2789 - 2803, http://dx.doi.org/10.1093/neuonc/noaf163

Lei Y; Hetherington K; Daly R; Rensen N; McGill BC; Ziegler DS; Lau LMS; Tyrrell V; Karpelowsky J; Cowley MJ; Tucker KM; Haber M; Barahona P; Wakefield CE, 2025, 'Data Sharing, Biopsies and Patient Confidentiality in a Precision Medicine Trial for Childhood Cancer: A Mixed Method Study of Parents, Oncologists, and Scientists’ Perspectives', Journal of Personalized Medicine, 15, http://dx.doi.org/10.3390/jpm15110531

Trinder SM; Ziegler DS; Lau LMS, 2025, 'From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology', Targeted Oncology, 20, pp. 907 - 915, http://dx.doi.org/10.1007/s11523-025-01178-w

Laetsch TW; Alvaro RH; Ziegler D; Kang HJ; Albert C; Watt TC; Fetzko SL; Arakawa A; Nysom K; Rigaud C; Suriyapperuma S; Sharma N; Peterson P; Wright J; Morgenstern D, 2025, 'OR28-05 Selpercatinib in Pediatric and Adolescent Patients with RET-Altered Solid Tumors: Safety and Efficacy Results from the Phase 1/2 LIBRETTO-121 Study', Journal of the Endocrine Society, 9, http://dx.doi.org/10.1210/jendso/bvaf149.1746

Doz F; Casanova M; Koh K-N; Nysom K; Canete A; Kang HJ; Karajannis M; Hargrave D; Corradini N; Wu Y; Wang H; Ziegler D; Prud'homme N; Manzitti C; Campbell-Hewson Q; Sturm-Pellanda C; Xu T; Sutaria DS; Fultang L; Devlin C; Mussai F; Gajjar AJ, 2025, 'Abstract A017-PR013: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: An update from the iMATRIX alectinib phase I/II open-label, multi-center study', Cancer Research, 85, http://dx.doi.org/10.1158/1538-7445.pediatric25-a017-pr013

Fuentes-Bolanos NA; Sylvester D; Courtney E; Mayoh C; Warby M; Khuong Quang DA; Barahona P; Sullivan A; Altekoester A; Rumford M; Dholaria H; Wong M; Tyrrell V; Haber M; Tucker K; Cowley MJ; Ziegler DS; Pinese M; Lau LMS, 2025, 'Cooperation between germline and somatic drivers in childhood cancer: insights from the ZERO cohort', CANCER RESEARCH, 85, pp. A45 - A45, http://dx.doi.org/10.1158/1538-7445.PEDIATRIC25-A045

Raiti L; Altekoester A; El-Kamand S; Ryan G; Tucker K; Warby M; Courtney E; Barahona P; Lau L; Trahair T; Marshall G; Ziegler D; Haber M; Tyrrell V; Cowley M; Mayoh C; Pinese M; Khuong-Quang D-A; Fuentes-Bolanos N, 2025, 'The biology of childhood tumors with germline CHEK2 loss of function variants', CANCER RESEARCH, 85, pp. A44 - A44, http://dx.doi.org/10.1158/1538-7445.PEDIATRIC25-A044

Lau LMS; Salomon R; Chen W; Shale C; Toumari M; Li W; Chan J; Razavi-Bazaz S; Cui L; El-Kamand S; Wong M; Cuppen E; Haber M; Tyrrell V; Ekert PG; Ziegler DS; Priestley P; Cowley MJ, 2025, 'Whole-genome-based, tumor-informed circulating tumor DNA detection correlates with treatment response and survival of pediatric solid tumor', CANCER RESEARCH, 85, pp. A001PR9 - A001PR9, http://dx.doi.org/10.1158/1538-7445.PEDIATRIC25-A001-PR009

Beaulieu A; Ducharme J; Thibeault C; Akani BC; Ziegler D; Hogan D; Corrêa GC; Reynolds HW; Johri M, 2025, 'The Immunization Agenda 2030 Strategy to reach zero-dose children in low-income and middle-income countries: a scoping review', BMJ Global Health, 10, http://dx.doi.org/10.1136/bmjgh-2024-018293

Xie T; Sorenson JC; Spector LG; Pankratz N; Huang RS; Hiyama E; Poynter JN; Tomlinson GE; Armengol C; Kappler R; Scheurer ME; Roman E; Castellano A; Grotzer MA; Ziegler DS; Basu S; Marcotte EL; Yang T, 2025, 'Multiancestry Transcriptome-Wide Association Study Identifies Candidate Genes Associated with Hepatoblastoma', Cancer Epidemiology Biomarkers and Prevention, 34, pp. 1405 - 1414, http://dx.doi.org/10.1158/1055-9965.EPI-24-1553

Pereira R; Mackay A; Grabovska Y; Bradley A; Bloom T; Nicoll J; Boche D; Procter J; Maybury M; Schagen J; Walker L; Roncaroli F; Karabatsou K; Ogunbiyi O; van Dalen T; Sidpra J; Rossi S; Miele E; Ziegler DS; Shi Z; Jacques TS; Hargrave D; Zebian B; Bleil C; Yates J; Norton E; Mandeville H; Creak A; Welsh L; Marshall L; Carceller F; Vaidya SJ; Reisz Z; Al-Sarraj S; Mastronuzzi A; Carai A; Vinci M; Kurian KM; Ng HK; Brandner S; Jones C; Clarke M, 2025, 'The Spectrum of IDH-and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations', Clinical Cancer Research, 31, pp. 3259 - 3275, http://dx.doi.org/10.1158/1078-0432.CCR-24-1256

Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K, 2025, 'Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (Nature Medicine, (2024), 30, 1, (207-217), 10.1038/s41591-023-02668-y)', Nature Medicine, 31, pp. 2454, http://dx.doi.org/10.1038/s41591-025-03709-4

Back to profile page